GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Cyclically Adjusted PB Ratio

Resverlogix (TSX:RVX) Cyclically Adjusted PB Ratio : (As of Jun. 11, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Resverlogix Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Resverlogix's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Cyclically Adjusted PB Ratio Chart

Resverlogix Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Resverlogix Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Resverlogix's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Resverlogix's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resverlogix's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Resverlogix's Cyclically Adjusted PB Ratio falls into.



Resverlogix Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Resverlogix's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Resverlogix's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.36/126.2576*126.2576
=-0.360

Current CPI (Mar. 2024) = 126.2576.

Resverlogix Quarterly Data

Book Value per Share CPI Adj_Book
201404 -0.850 98.920 -1.085
201407 -0.680 99.315 -0.864
201410 -0.702 99.473 -0.891
201501 -0.779 98.209 -1.001
201504 -1.056 99.710 -1.337
201507 -0.427 100.579 -0.536
201510 -0.478 100.500 -0.601
201601 -0.636 100.184 -0.802
201604 -0.688 101.370 -0.857
201607 -0.777 101.844 -0.963
201610 -0.977 102.002 -1.209
201701 -1.131 102.318 -1.396
201704 -1.292 103.029 -1.583
201707 -1.269 103.029 -1.555
201710 -1.307 103.424 -1.596
201801 -0.557 104.056 -0.676
201804 -0.601 105.320 -0.720
201807 -0.984 106.110 -1.171
201810 -1.075 105.952 -1.281
201901 -1.066 105.557 -1.275
201904 -1.387 107.453 -1.630
201907 -1.246 108.243 -1.453
201910 -0.517 107.927 -0.605
202001 -0.465 108.085 -0.543
202004 -0.425 107.216 -0.500
202007 -0.418 108.401 -0.487
202010 -0.298 108.638 -0.346
202103 -0.209 110.298 -0.239
202106 -0.195 111.720 -0.220
202109 -0.227 112.905 -0.254
202112 -0.315 113.774 -0.350
202203 -0.309 117.646 -0.332
202206 -0.306 120.806 -0.320
202209 -0.304 120.648 -0.318
202212 -0.303 120.964 -0.316
202303 0.000 122.702 0.000
202306 -0.330 124.203 -0.335
202309 -0.356 125.230 -0.359
202312 -0.367 125.072 -0.370
202403 -0.360 126.258 -0.360

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Resverlogix  (TSX:RVX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Resverlogix Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Resverlogix's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Resverlogix (TSX:RVX) Business Description

Industry
Traded in Other Exchanges
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Executives
Aaron Bradley Cann Senior Officer

Resverlogix (TSX:RVX) Headlines

No Headlines